CasRx RNA Targeting System for Viral Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for RNA viruses such as Enterovirus 71 (EV71), Coxsackievirus, and Parechovirus are inadequate, with limited efficacy and potential side effects, and there is a lack of commercially available vaccines or therapeutics for prevention or treatment.
Innovation Solution
A molecular system comprising an RNA-guided RNA-targeting effector protein, such as CasRx, and guide RNA molecules (gRNAs) that are at least 70-100% identical to specific sequences, is administered to target and cleave RNA viral genomes, disrupting replication and viral functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics such as antibodies treatment are used, then viral infections can be targeted, but manufacturing bottlenecks and distribution limitations occur
Solution Approach 1:
The patent replaces the mechanical/biological system of antibody production and administration with a molecular biology-based CRISPR system. Instead of using complex antibody molecules that require sophisticated manufacturing and cold chain distribution, the invention uses programmable guide RNA molecules that can be synthesized in vitro and delivered more simply, substituting a complex biological system with a more manufacturable molecular system.
Solution Approach 2:
The patent changes the fundamental parameter of therapeutic action from antibody-antigen binding to CRISPR-Cas guided RNA cleavage. By changing the mechanism of action from immunological recognition to programmable molecular targeting, the system achieves both therapeutic efficacy and improved manufacturability through in vitro synthesis of guide RNAs.
2Reliability
If human intravenous immunoglobulin and monoclonal antibodies are used, then viral infections can be treated, but antibody-dependent enhancement and cell-mediated cytotoxicity risks occur
Solution Approach 1:
The patent substitutes the immunological mechanism of antibodies with a molecular biology mechanism using CRISPR-Cas proteins and guide RNAs. This replacement eliminates the harmful immunological effects (ADE and ADCC) because the system directly cleaves viral RNA through programmed nuclease activity rather than through immune cell activation, removing the pathway to harmful side effects.
Solution Approach 2:
The patent introduces guide RNA molecules as intermediaries that program the Cas protein to specifically target and cleave viral RNA. This intermediary mechanism provides precise control over targeting specificity through sequence complementarity, eliminating the non-specific and potentially harmful immunological responses associated with antibody therapy.
3Ease of manufacture
If no specific vaccine or therapeutic is available, then manufacturing costs are reduced, but disease prevention and treatment capability are lost
Solution Approach 1:
The patent employs preliminary action by designing and synthesizing guide RNA molecules in advance that are specific to viral sequences. These pre-designed guide RNAs can be stored and deployed rapidly when needed, combining the simplicity of off-the-shelf molecular products with the reliability of targeted antiviral therapy. The guide RNAs are prepared beforehand with high sequence specificity to ensure effective viral targeting.
Solution Approach 2:
The patent replaces complex vaccine development and manufacturing processes with a molecular synthesis approach using CRISPR components. Instead of requiring live virus cultivation, cell culture, and complex formulation for vaccines, the system uses in vitro transcription and purification of guide RNAs, which is simpler, faster, and equally effective at providing disease prevention and treatment capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The molecular system effectively inhibits viral replication and reduces viral titers by up to 3-4 logs, providing a potential therapeutic and prophylactic solution for RNA virus infections.
Implementation Method 1
each of the one or more guide RNAs comprise a guide sequence that is at least 70%, at least 80%, at least 90%, at least 95%, or 100% identical to one of the sequences set forth in SEQ ID NO: 1 to 6
Implementation Method 2
The molecular system effectively inhibits viral replication and reduces viral titers by up to 3-4 logs
Data Source
AI summary
Disclosed herein are molecular systems comprising an RNA-guided RNA-targeting effector protein, and one or more guide RNA molecule (gRNA). Also disclosed herein are guide RNA molecules for use in the systems disclosed herein, as well as the use of the described systems in the treatment or prevention of disease.